The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Twenty-one gene recurrence scores in individuals with breast cancer associated with CHEK2 and ATM germline pathogenic variants.
 
Payal Deepak Shah
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Johnson & Johnson (I); Merck (I); Novartis (I); Novo Nordisk; Novo Nordisk (I); Pfizer (I)
Consulting or Advisory Role - Daiichi Sankyo; Gilead Sciences
Research Funding - AstraZeneca (Inst); Zenith Epigenetics (Inst)
 
Jamie Brower
No Relationships to Disclose
 
Lauren Cuff
No Relationships to Disclose
 
Robert Richardville
No Relationships to Disclose
 
Jada G. Hamilton
No Relationships to Disclose
 
Judy Ellen Garber
Consulting or Advisory Role - Aleta BioTherapeutics (I); GTx (I); H3 Biomedicine (I); Kronos Bio (I); Novartis (I)
Research Funding - Ambry Genetics; InVitae; Novartis (I)
Other Relationship - AACR; Adrienne Helis Malvin Medical Research Foundation (I); Breast Cancer Research Foundation; Diana Helis Henry Medical Foundation (I); Facing our Risk of Cancer Empowered; James P. Wilmot Foundation (I)
 
Siddhartha Yadav
Research Funding - REPARE Therapeutics (Inst)
 
Fergus Couch
Honoraria - Ambry Genetics/Konica Minolta; Natera; US Oncology Network
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Ambry Genetics; Qiagen
Research Funding - GRAIL
Travel, Accommodations, Expenses - GRAIL
Other Relationship - Ambry Genetics
 
Kenneth Offit
Patents, Royalties, Other Intellectual Property - Patent pending on therapeutic applications of targeting ERCC3 mutations in cancer. Diagnosis & treatment of ercc3-mutant cancer US20210137850A1
Other Relationship - AnaNeo Therapeutics
 
Susan M. Domchek
Honoraria - AstraZeneca; GlaxoSmithKline
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst)
 
Mark E. Robson
Consulting or Advisory Role - Change HealthCare
Research Funding - AstraZeneca (Inst); Merck (Inst); Pfizer (Inst); Zenith Pharmaceuticals (Inst)
Other Relationship - AstraZeneca; Clinical Care Options; Clinical Education Alliance; MJH Healthcare Holdings, LLC; MyMedEd; Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Artios; Daiichi Sankyo; Epic Sciences; Merck; Pfizer; Tempus; Zenith Pharmaceuticals